Seroprevalence of SARS-CoV-2 in Strasbourg University Hospital, Strasbourg, France (COVID-19)

NACompletedINTERVENTIONAL
Enrollment

1,466

Participants

Timeline

Start Date

April 17, 2020

Primary Completion Date

May 7, 2020

Study Completion Date

July 16, 2021

Conditions
SARS-CoV-2 Serological StatusSARS-CoV-2 Seroprevalence
Interventions
DIAGNOSTIC_TEST

Blood sample for serological test

"Serology tests:~* By LFA-ICT: BIOSYNEX COVID-19 BSS reference SW40005, BIOSYNEX SWISS SA, Fribourg, Switzerland~* ELISA: EDI™ Novel Coronavirus COVID-19 ELISA IgG Kit, Epitope Diagnostics, Inc., San Diego, USA~Confirmation test by seroneutralization tests developed at the Strasbourg Virology laboratory on whole virus (analyzes performed in a biosafety level 3 laboratory) and by the viral pseudoparticles system, will be performed."

Trial Locations (1)

Unknown

Hôpitaux Universitaires de Strasbourg - Centre d'Investigation Clinique - Nouvel Hôpital Civil et Hautepierre, Strasbourg

All Listed Sponsors
lead

University Hospital, Strasbourg, France

OTHER

NCT04441684 - Seroprevalence of SARS-CoV-2 in Strasbourg University Hospital, Strasbourg, France (COVID-19) | Biotech Hunter | Biotech Hunter